Leerink upgrades this beaten-down biotech stock, says investors should buy the dip - Buy this biotech stock that can rally more than 65%, Goldman says - This little-known biotech stock is a buy that's primed to double in price, Goldman says - This biotech stock is an 'oncology powerhouse' with 40% upside, says Truist Securities - These innovative biotech stocks have a good chance of breaking out in 2025 - Wells Fargo sees this biotech stock rallying 75% in its bull case - JPMorgan's top biotech stock picks for 2025 as sector looks for a comeback year - These 9 biotech stocks have doubled this year and are set to double again, analysts say - UK biotech, what's in it for retail investors? - Goldman Sachs says buy this biotech stock with more than 60% upside